Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
15,843
archived clinical trials in
Prostate Cancer

In Vivo Dosimetry During Prostate Cancer Radiotherapy
Pilot Study to Evaluate In Vivo Plastic Scintillation Detectors for Real-Time Radiation Dosimetry During Prostate Cancer Radiotherapy
Status: Enrolling
Updated:  4/4/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
In Vivo Dosimetry During Prostate Cancer Radiotherapy
Pilot Study to Evaluate In Vivo Plastic Scintillation Detectors for Real-Time Radiation Dosimetry During Prostate Cancer Radiotherapy
Status: Enrolling
Updated: 4/4/2016
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Semen Analysis After Proton Therapy for Prostate Cancer
Semen Analysis Following Definitive Treatment of Prostate Cancer With Proton Radiation Therapy Alone
Status: Enrolling
Updated:  4/5/2016
University of Florida Proton Therapy Institute
mi
from
Jacksonville, FL
Semen Analysis After Proton Therapy for Prostate Cancer
Semen Analysis Following Definitive Treatment of Prostate Cancer With Proton Radiation Therapy Alone
Status: Enrolling
Updated: 4/5/2016
University of Florida Proton Therapy Institute
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Energy Balance for Prostate Cancer Survivorship
Energy Balance for Prostate Cancer Survivorship
Status: Enrolling
Updated:  4/5/2016
University of Kansas Medical Center
mi
from
Kansas City, KA
Energy Balance for Prostate Cancer Survivorship
Energy Balance for Prostate Cancer Survivorship
Status: Enrolling
Updated: 4/5/2016
University of Kansas Medical Center
mi
from
Kansas City, KA
Click here to add this to my saved trials
Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
A Phase I/II Trial of AN-152 [AEZS-108) in Castration- and Taxane-Resistant Prostate Cancer
Status: Enrolling
Updated:  4/6/2016
University of Southern California
mi
from
Los Angeles, CA
Doxorubicin-GnRH Agonist Conjugate AEZS-108 in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
A Phase I/II Trial of AN-152 [AEZS-108) in Castration- and Taxane-Resistant Prostate Cancer
Status: Enrolling
Updated: 4/6/2016
University of Southern California
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Phase 2 Trial of TAK-700 (Orteronel) Without Prednisone for Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  4/6/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Orteronel in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer
Phase 2 Trial of TAK-700 (Orteronel) Without Prednisone for Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 4/6/2016
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Prostate Cancer Parameters for Patients Receiving Proton Treatment
Longitudinal Study for the Evaluation of Safety and Efficacy Parameters in Prostate Cancer Patients Treated at IU Health Proton Therapy Center (IUHPTC)
Status: Enrolling
Updated:  4/6/2016
Iu Health Proton Therapy Center
mi
from
Bloomington, IN
Prostate Cancer Parameters for Patients Receiving Proton Treatment
Longitudinal Study for the Evaluation of Safety and Efficacy Parameters in Prostate Cancer Patients Treated at IU Health Proton Therapy Center (IUHPTC)
Status: Enrolling
Updated: 4/6/2016
Iu Health Proton Therapy Center
mi
from
Bloomington, IN
Click here to add this to my saved trials
A Study of PNT2258 in Patients With Advanced Solid Tumors
A Phase 1 Study of PNT2258 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated:  4/11/2016
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
A Study of PNT2258 in Patients With Advanced Solid Tumors
A Phase 1 Study of PNT2258 in Patients With Advanced Solid Tumors
Status: Enrolling
Updated: 4/11/2016
South Texas Accelerated Research Therapeutics
mi
from
San Antonio, TX
Click here to add this to my saved trials
Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial
Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial
Status: Enrolling
Updated:  4/12/2016
Groupe Health Cooperative, Veterans Adminstration Hospital and University of Washington
mi
from
Seattle, WA
Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial
Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial
Status: Enrolling
Updated: 4/12/2016
Groupe Health Cooperative, Veterans Adminstration Hospital and University of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial
Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial
Status: Enrolling
Updated:  4/12/2016
Seattle Prostate Institute
mi
from
Seattle, WA
Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial
Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial
Status: Enrolling
Updated: 4/12/2016
Seattle Prostate Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial
Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial
Status: Enrolling
Updated:  4/12/2016
Schiffler Cancer Center
mi
from
Wheeling, WV
Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial
Implant and External Radiation for Prostate Cancer With or Without Hormonal Therapy: A Prospective Randomized Trial
Status: Enrolling
Updated: 4/12/2016
Schiffler Cancer Center
mi
from
Wheeling, WV
Click here to add this to my saved trials
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/13/2016
Investigative Site #10
mi
from
Goodyear, AZ
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/13/2016
Investigative Site #10
mi
from
Goodyear, AZ
Click here to add this to my saved trials
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/13/2016
Investigative Site: #42
mi
from
Greenbrae, CA
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/13/2016
Investigative Site: #42
mi
from
Greenbrae, CA
Click here to add this to my saved trials
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/13/2016
Investigative Site: #39
mi
from
Denver, CO
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/13/2016
Investigative Site: #39
mi
from
Denver, CO
Click here to add this to my saved trials
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/13/2016
Investigative Site: #34
mi
from
Detroit, MI
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/13/2016
Investigative Site: #34
mi
from
Detroit, MI
Click here to add this to my saved trials
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/13/2016
Investigative Site: #34
mi
from
St. Louis, MO
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/13/2016
Investigative Site: #34
mi
from
St. Louis, MO
Click here to add this to my saved trials
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/13/2016
Investigative Site: #36
mi
from
Las Vegas, NV
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/13/2016
Investigative Site: #36
mi
from
Las Vegas, NV
Click here to add this to my saved trials
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/13/2016
Investigative Site: # 37
mi
from
Oklahoma City, OK
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/13/2016
Investigative Site: # 37
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/13/2016
Investigative Site: # 33
mi
from
San Antonio, TX
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/13/2016
Investigative Site: # 33
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  4/13/2016
Investigative Site: #74
mi
from
Arkhangelsk,
A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
A Phase 2 Study to Determine the Efficacy and Safety of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 4/13/2016
Investigative Site: #74
mi
from
Arkhangelsk,
Click here to add this to my saved trials
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  4/14/2016
Investigative Site #04
mi
from
Los Angeles, CA
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 4/14/2016
Investigative Site #04
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  4/14/2016
Investigative Site #14
mi
from
San Francisco, CA
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 4/14/2016
Investigative Site #14
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  4/14/2016
Investigative Site #02
mi
from
Fort Meyers, FL
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 4/14/2016
Investigative Site #02
mi
from
Fort Meyers, FL
Click here to add this to my saved trials
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  4/14/2016
Clinical Research Facility
mi
from
Ann Arbor, MI
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 4/14/2016
Clinical Research Facility
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  4/14/2016
Clinical Research Facility
mi
from
New York, NY
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 4/14/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  4/14/2016
Clinical Research Facility
mi
from
Chapel Hill, NC
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 4/14/2016
Clinical Research Facility
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  4/14/2016
Clinical Research Facility
mi
from
Cleveland, OH
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 4/14/2016
Clinical Research Facility
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated:  4/14/2016
Clinical Research Facility
mi
from
Nashville, TN
A Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
An Open Label, Multicenter, Phase 2 Study to Determine the Safety and Efficacy of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension), Administered to Patients With Metastatic Castration-Resistant Prostate Cancer
Status: Enrolling
Updated: 4/14/2016
Clinical Research Facility
mi
from
Nashville, TN
Click here to add this to my saved trials
Understanding and Discouraging Overuse of Potentially Harmful Screening Tests
Understanding and Discouraging Overuse of Potentially Harmful Screening Tests
Status: Enrolling
Updated:  4/15/2016
Duke Primary Care Research Consortium
mi
from
Durham, NC
Understanding and Discouraging Overuse of Potentially Harmful Screening Tests
Understanding and Discouraging Overuse of Potentially Harmful Screening Tests
Status: Enrolling
Updated: 4/15/2016
Duke Primary Care Research Consortium
mi
from
Durham, NC
Click here to add this to my saved trials
Anatomical and Functional Differences Between Continent and Incontinent Men Post Radical Prostatectomy
Status: Enrolling
Updated:  4/20/2016
VA Ann Arbor Healthcare System
mi
from
Ann Arbor, MI
Anatomical and Functional Differences Between Continent and Incontinent Men Post Radical Prostatectomy
Status: Enrolling
Updated: 4/20/2016
VA Ann Arbor Healthcare System
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Anatomical and Functional Differences Between Continent and Incontinent Men Post Radical Prostatectomy
Status: Enrolling
Updated:  4/20/2016
University of Michigan
mi
from
Ann Arbor, MI
Anatomical and Functional Differences Between Continent and Incontinent Men Post Radical Prostatectomy
Status: Enrolling
Updated: 4/20/2016
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma
Phase I Dose Escalation and Landmark Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma (UTUC) Following Endoscopic Resection
Status: Enrolling
Updated:  4/21/2016
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Phase I Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma
Phase I Dose Escalation and Landmark Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma (UTUC) Following Endoscopic Resection
Status: Enrolling
Updated: 4/21/2016
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
The Biodistribution and Potential Diagnostic Ability of 18F FACBC in Patients With Head and Neck, Breast, and Prostate Cancer
Pilot Study Investigating the Biodistribution and Potential Diagnostic Ability of 18F FACBC in Patients With Head and Neck, Breast, and Prostate Cancer
Status: Enrolling
Updated:  5/4/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
The Biodistribution and Potential Diagnostic Ability of 18F FACBC in Patients With Head and Neck, Breast, and Prostate Cancer
Pilot Study Investigating the Biodistribution and Potential Diagnostic Ability of 18F FACBC in Patients With Head and Neck, Breast, and Prostate Cancer
Status: Enrolling
Updated: 5/4/2016
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Problem Solving Therapy for Prostate Cancer Spousal Caregivers
Problem-Solving Therapy for Prostate Cancer Patient's Spousal Caregivers
Status: Enrolling
Updated:  5/5/2016
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Problem Solving Therapy for Prostate Cancer Spousal Caregivers
Problem-Solving Therapy for Prostate Cancer Patient's Spousal Caregivers
Status: Enrolling
Updated: 5/5/2016
UC San Diego Moores Cancer Center
mi
from
La Jolla, CA
Click here to add this to my saved trials
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
A Phase I Study of the mTOR Inhibitor Temsirolimus in Combination With the HDAC Inhibitor Vorinostat in Patients With Metastatic Prostate Cancer
Status: Enrolling
Updated:  5/9/2016
The Sydney Kimmel Comprehensive Center at John Hopkins
mi
from
Baltimore, MD
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
A Phase I Study of the mTOR Inhibitor Temsirolimus in Combination With the HDAC Inhibitor Vorinostat in Patients With Metastatic Prostate Cancer
Status: Enrolling
Updated: 5/9/2016
The Sydney Kimmel Comprehensive Center at John Hopkins
mi
from
Baltimore, MD
Click here to add this to my saved trials
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
A Phase I Study of the mTOR Inhibitor Temsirolimus in Combination With the HDAC Inhibitor Vorinostat in Patients With Metastatic Prostate Cancer
Status: Enrolling
Updated:  5/9/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
A Phase I Study of the mTOR Inhibitor Temsirolimus in Combination With the HDAC Inhibitor Vorinostat in Patients With Metastatic Prostate Cancer
Status: Enrolling
Updated: 5/9/2016
Roswell Park Cancer Institute
mi
from
Buffalo, NY
Click here to add this to my saved trials
Prostate Cancer Utilities and Cost-Effectiveness Analysis
Prostate Cancer Utilities and Cost-Effectiveness Analysis
Status: Enrolling
Updated:  5/17/2016
University of Chicago
mi
from
Chicago, IL
Prostate Cancer Utilities and Cost-Effectiveness Analysis
Prostate Cancer Utilities and Cost-Effectiveness Analysis
Status: Enrolling
Updated: 5/17/2016
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Effects of ASA on Prostate Tissue
In Vivo Molecular Effects of Aspirin on Prostate Tissue
Status: Enrolling
Updated:  5/24/2016
VA Puget Sound Health Care Service
mi
from
Seattle, WA
Effects of ASA on Prostate Tissue
In Vivo Molecular Effects of Aspirin on Prostate Tissue
Status: Enrolling
Updated: 5/24/2016
VA Puget Sound Health Care Service
mi
from
Seattle, WA
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Center for Urological Research
mi
from
La Mesa, CA
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Center for Urological Research
mi
from
La Mesa, CA
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
San Bernadino Urological Associates
mi
from
San Bernardino, CA
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
San Bernadino Urological Associates
mi
from
San Bernardino, CA
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Grove Hill Medical Center Urology
mi
from
New Britain, CT
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Grove Hill Medical Center Urology
mi
from
New Britain, CT
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Innovative Surgical Resources
mi
from
Tampa, FL
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Innovative Surgical Resources
mi
from
Tampa, FL
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Medical and Surgical Specialists, LLC
mi
from
Galesburg, IL
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Peoria Urological Associates
mi
from
Peoria, IL
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Peoria Urological Associates
mi
from
Peoria, IL
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Oncology Hematology Associates of SW Indiana
mi
from
Evansville, IN
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Oncology Hematology Associates of SW Indiana
mi
from
Evansville, IN
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Center for Cancer Care at Goshen Health System
mi
from
Goshen, IN
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Center for Cancer Care at Goshen Health System
mi
from
Goshen, IN
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Indiana University Cancer Center
mi
from
Indianapolis, IN
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Indiana University Cancer Center
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Quality Cancer Center (MCGOP)
mi
from
Indianapolis, IN
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Quality Cancer Center (MCGOP)
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Urology of Indiana, LLC
mi
from
Indianapolis, IN
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Urology of Indiana, LLC
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Urology Associates
mi
from
Muncie, IN
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Urology Associates
mi
from
Muncie, IN
Click here to add this to my saved trials
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated:  5/25/2016
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Ability of Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy: Hoosier Oncology Group GU02-41
Status: Enrolling
Updated: 5/25/2016
Northern Indiana Cancer Research Consortium
mi
from
South Bend, IN
Click here to add this to my saved trials